ReviewVaccines2025
Overcoming Barriers to Human Papillomavirus Vaccination in Guangdong Province, China.
Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Epidemiologic burden, clinical attribution, and implications for immunization strategies of HPV infection among males in Sichuan, China: a large-sample cross-sectional study.Virology journal · 2026Article
- Epidemiology and prevention of HPV-driven cervical cancer in urban-rural China: a population-based study of 60,280 women.Scientific reports · 2026Article
- Cost-effectiveness and epidemiological impact of gender-neutral vaccination against human papillomavirus in economically developed metropolises of Beijing, Shanghai, and Guangzhou, China.Human vaccines & immunotherapeutics · 2025Article
- Addressing male HPV vaccination in China: A narrative review of challenges and opportunities.Human vaccines & immunotherapeutics · 2025Review
- Phylogenetics and selective pressure analysis of human papillomavirus types 31 and 33 variants in Eastern China.BMC infectious diseases · 2025Article
- Exploring the willingness to pay for HPV vaccines and price sensitivity among Chinese college students: the impact of health literacy and vaccine hesitancy.Frontiers in public health · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Human papillomavirus (HPV) infection remains a critical public health challenge in China, particularly in Guangdong Province, where HPV-52, 16, and 58 genotypes predominate, and male infection rates exceed 40%. Despite the successful implementation of a government-funded school-based program that has achieved 88% HPV vaccine coverage among adolescent girls, several persistent barriers, including genotype mismatch (the free HPV vaccine covers < 50% of high-risk local strains), regional disparities (80% vs. 60% for first-dose coverage), and exclusion of males, thwart progress toward herd immunity. Financial sustainability risks pose an even more significant threat to the expansion of HPV vaccination programs, especially in Guangdong province where annual expenditures exceed CNY 200 million. This review delves into Guangdong's pioneering efforts and proposes practical solutions: accelerating domestic multivalent HPV vaccine development, adopting gender-neutral vaccination policies, and leveraging mobile clinics for remote populations. These strategies not only provide a roadmap for China but also serve as valuable insight for other LMICs striving to overcome HPV-related inequalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.